EVX-01 personalized cancer vaccine moves into focus as Evaxion examines broader immune responses
Evaxion advances EVX-01 melanoma vaccine research with new Phase 2 immune biomarker data. Explore its 75% response rate and future potential.
Pharma & Biotech